---
schema_version: "secwatch.filing_event.v1"
accession: "0001596783-23-000187"
form_type: "8-K/A"
ticker: null
cik: "0001596783"
company_name: "Catalent, Inc."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:35:57.762772+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Catalent revises FY2023 and Q1 FY2024 prelim results; goodwill impairment $689M

## Summary
- FY2023 Adjusted EBITDA reduced by $17M to $697M; net loss per share widened from $(1.29) to $(1.42).
- Q4 FY2023 Adjusted EBITDA fell $17M to $122M; net loss per share increased to $(0.59) from $(0.48).
- Q1 FY2024 net loss increased $44M to $759M, including $53M tax valuation allowance; goodwill impairment adjusted to $689M.
- Q1 FY2024 Adjusted EBITDA decreased $3M to $112M; adjusted net loss per share $(0.13) vs preliminary $(0.10).
- FY2024 guidance unchanged; revisions are non-cash and included in filed 10-K and 10-Q.

## SEC filing metadata
- accession: 0001596783-23-000187
- form_type: 8-K/A
- cik: 0001596783
- company_name: Catalent, Inc.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.06, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/ctlt-20231208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001596783-23-000187
- JSON: https://secwatch.observer/filing/0001596783-23-000187.json
- Plain text: https://secwatch.observer/filing/0001596783-23-000187.txt

## Key facts
- Earnings Releases
  Catalent, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended June 30, 2023.
  - Period: the fourth quarter and fiscal year ended June 30, 2023
  - Result: preliminary results
  source text: On August 29, 2023, the Company issued an earnings release setting forth the Company's preliminary fourth quarter and fiscal year ended June 30, 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm
- Earnings Releases
  Catalent, Inc. reported preliminary financial results for the first quarter ended September 30, 2023.
  - Period: the first quarter ended September 30, 2023
  - Result: preliminary results
  source text: In addition, on November 15, 2023, the Company issued an earnings release setting forth the Company's preliminary first quarter ended September 30, 2023 financial results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm
- Restructurings & Charges
  Catalent, Inc. announced a impairment with charges of fixed asset impairment charges primarily associated with an idle facility in the Biologics segment affecting Biologics.
  - Type: impairment
  - Charge: fixed asset impairment charges primarily associated with an idle facility in the Biologics segment
  - Affected area: Biologics
  source text: Revisions to unallocated costs represent fixed asset impairment charges primarily associated with an idle facility in the Biologics segment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm
- Restructurings & Charges
  Catalent, Inc. announced a impairment with charges of $689 million of non-cash goodwill impairment charges affecting Biologics.
  - Type: impairment
  - Charge: $689 million of non-cash goodwill impairment charges
  - Affected area: Biologics
  source text: For the three months ended September 30, 2023, unallocated costs include $689 million of non-cash goodwill impairment charges.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.